- Home
- LCTX vs HTCO Comparison
LCTX vs HTCO Comparison
Compare LCTX & HTCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- HTCO
- Stock Information
- Founded
- LCTX 1990
- HTCO N/A
- Country
- LCTX United States
- HTCO Singapore
- Employees
- LCTX N/A
- HTCO 31
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- HTCO
- Sector
- LCTX Health Care
- HTCO
- Exchange
- LCTX Nasdaq
- HTCO NYSE
- Market Cap
- LCTX 110.2M
- HTCO 210.6M
- IPO Year
- LCTX N/A
- HTCO N/A
- Fundamental
- Price
- LCTX $0.55
- HTCO $2.30
- Analyst Decision
- LCTX Strong Buy
- HTCO
- Analyst Count
- LCTX 4
- HTCO 0
- Target Price
- LCTX $5.25
- HTCO N/A
- AVG Volume (30 Days)
- LCTX 3.9M
- HTCO 151.6K
- Earning Date
- LCTX 11-14-2024
- HTCO 02-15-2025
- Dividend Yield
- LCTX N/A
- HTCO N/A
- EPS Growth
- LCTX N/A
- HTCO N/A
- EPS
- LCTX N/A
- HTCO N/A
- Revenue
- LCTX $8,719,000.00
- HTCO $80,567,672.00
- Revenue This Year
- LCTX N/A
- HTCO N/A
- Revenue Next Year
- LCTX $123.52
- HTCO N/A
- P/E Ratio
- LCTX N/A
- HTCO N/A
- Revenue Growth
- LCTX N/A
- HTCO N/A
- 52 Week Low
- LCTX $0.48
- HTCO $0.21
- 52 Week High
- LCTX $1.61
- HTCO $2.78
- Technical
- Relative Strength Index (RSI)
- LCTX 41.03
- HTCO N/A
- Support Level
- LCTX $0.48
- HTCO N/A
- Resistance Level
- LCTX $0.57
- HTCO N/A
- Average True Range (ATR)
- LCTX 0.05
- HTCO 0.00
- MACD
- LCTX 0.01
- HTCO 0.00
- Stochastic Oscillator
- LCTX 48.36
- HTCO 0.00
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About HTCO CARAVELLE INTERNATIONAL GROUP
Caravelle International Group is an international operator of ocean transportation services. It is engaged in the seaborne transportation service under voyage contracts as well as vessel service for and on behalf of ship owners. The company has two operating segments namely, ocean transport and Heating business. The company derives the majority of its revenue from the Ocean transportation business. The company derives freight revenue from voyage contracts and provides vessel service.